Streetbeat News

Products Services

IMMX

Immix Biopharma has advanced its CAR-T therapy, NXC-201, to a higher dose level in its U.S. trial for AL Amyloidosis. The trial, NEXICART-2, is now dosing at 450 million CAR+T cells, following successful results at a lower dose. NXC-201 is the only one-time CAR-T treatment for this condition in U.S. trials.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:33 pm

AIPI

DAT

PLTR

Palantir Technologies has partnered with Edgescale AI to launch 'Live Edge', a solution to integrate AI in manufacturing and utilities. This partnership aims to simplify infrastructure and enhance operational efficiency. Palantir's stock has risen significantly over the past year, and investors can access it through ETFs like REX AI Equity Premium Income ETF and ProShares Big Data Refiners ETF.

Portfolio Pulse from Nabaparna Bhattacharya

October 02, 2024 | 1:26 pm

LI

TSLA

Tesla's Q3 deliveries exceeded consensus but fell short of whisper numbers, causing a 3.5% drop in premarket trading. Concerns include Model Y/3 sales and potential margin erosion from a financing plan in China. Despite strong sales, Tesla's stock remains under pressure.

Portfolio Pulse from Shanthi Rexaline

October 02, 2024 | 1:21 pm

F

Ford's Q3 U.S. retail sales increased by 4% to 504,039 vehicles, with electric vehicle sales totaling 23,509 units.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:18 pm

AREB

American Rebel Holdings' subsidiary, American Rebel Beverages, received a significant re-stocking order from Kansas' Standard Beverage for their American Rebel Light Lager. This indicates growing demand for their product.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:18 pm

IBIT

Charles Edwards of Capriole Investments predicts a bullish outlook for Bitcoin, driven by improving macro conditions and the impact of spot ETFs. He notes Bitcoin's correlation with gold and expects it to follow gold's upward trend. Recent inflows into iShares Bitcoin Trust highlight growing institutional interest.

Portfolio Pulse from Khyathi Dalal

October 02, 2024 | 1:16 pm

STLA

FCA US LLC reported a 20% year-over-year decrease in Q3 2024 U.S. sales, totaling 305,294 vehicles. Despite the decline, the company's market share increased from 7.2% in July to 8% in September, and inventory was reduced by 50K units. Incentives will continue across brands like Chrysler, Dodge, FIAT, Jeep, and Ram.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:13 pm

AAPL

BABA

NVDA

Jim Cramer advises investors to let 'hot money' flow out of Nvidia and Apple, suggesting potential short-term declines due to high valuations and post-iPhone slump. He recommends considering Alibaba for those looking at Chinese markets, citing its solid fundamentals despite regulatory challenges.

Portfolio Pulse from Surbhi Jain

October 02, 2024 | 1:11 pm

ZENA

ZenaTech has received FAA approval for the evaluation, testing, and demonstration of its ZenaDrone solutions in the U.S. This approval marks a significant step for ZenaTech in expanding its drone operations and market presence in the United States.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:09 pm

JNJ

Johnson & Johnson announced that their drug ERLEADA shows a significant survival benefit over enzalutamide in treating metastatic castration-sensitive prostate cancer, reducing the risk of death by 23% at 24 months. This was presented at the European Congress of Oncology Pharmacy.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:09 pm